• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    70 Stocks Moving In Monday's Mid-Day Session

    6/13/22 12:10:43 PM ET
    $ABVC
    $AEMD
    $AERC
    $ANY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABVC alert in real time by email

     

    Gainers

    • Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) jumped 84% to $1.4713 after it authorized a share repurchase program to acquire up to $1 million in common stock.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) rose 74% to $0.6012 after dropping more than 28% on Friday.
    • bluebird bio, Inc. (NASDAQ:BLUE) gained 41.2% to $5.26. The FDA's Advisory Committee has unanimously backed Bluebird bio’s gene therapy for a rare blood disorder.
    • ABVC BioPharma, Inc. (NASDAQ:ABVC) jumped 35.8% to $1.2225 after dipping 49% on Friday.
    • Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) gained 28% to $5.82.
    • Redbox Entertainment Inc. (NASDAQ:RDBX) shares rose 23.9% to $16.35 after jumping more than 39% on Friday.
    • AeroClean Technologies, Inc. (NASDAQ:AERC) gained 21.2% to $15.15.
    • Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) jumped 21.1% to $2.18. Ekso Bionics received FDA clearance to market its EksoNR robotic exoskeleton for use with multiple sclerosis patients.
    • OptiNose, Inc. (NASDAQ:OPTN) surged 18.9% to $2.20 after reporting top-line results of ReOpen2, its second Phase 3 clinical trial of XHANCE for the treatment of chronic sinusitis.
    • Belite Bio, Inc (NASDAQ:BLTE) gained 15.4% to $21.35.
    • Electro-Sensors, Inc. (NASDAQ:ELSE) gained 12.4% to $5.45. Electro-Sensors and Mobile X Global, Inc, a connectivity-as-a-service company, agreed to merge and re-name the combined company Mobile X Global, Inc.
    • Quanergy Systems, Inc. (NASDAQ:QNGY) rose 8.2% to $0.5840 after climbing 17% on Friday.

     

    Losers

    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) shares tumbled 64.3% to $0.1823 after the company announced it plans to file for Chapter 7 bankruptcy.
    • NaaS Technology Inc. ADR (NASDAQ:NAAS) shares dipped 55.5% to $7.59.
    • Applied Blockchain, Inc. (NASDAQ:APLD) dropped 49.5% to $1.3850.
    • TDH Holdings, Inc. (NASDAQ:PETZ) shares dipped 42.8% to $0.1580. TDH Holdings reported a 1-for-20 reverse stock split.
    • BIT Mining Limited (NYSE:BTCM) fell 38% to $1.20.
    • Revlon, Inc. (NYSE:REV) fell 30.5% to $1.4250. Shares dropped more than 50% to on Friday following a report the company was expected to file for bankruptcy.
    • ContraFect Corporation (NASDAQ:CFRX) dropped 26% to $3.29. WBB Securities, last week, upgraded ContraFect from Buy to Strong Buy and announced a $7 price target.
    • Drive Shack Inc. (NYSE:DS) fell 25% to $1.3498.
    • Permianville Royalty Trust (NYSE:PVL) fell 25% to $4.26.
    • MicroStrategy Incorporated (NASDAQ:MSTR) shares fell 24.8% to $153.17 in sympathy with the price of Bitcoin and Ethereum.
    • Astra Space, Inc. (NASDAQ:ASTR) shares fell 24% to $1.5350 after rocket failed to deliver NASA weather satellites to orbit on Sunday.
    • Caribou Biosciences, Inc. (NASDAQ:CRBU) dropped 22.2% to $5.40. Caribou Biosciences recently reported additional data from the CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress.
    • Volta Inc. (NYSE:VLTA) fell 22% to $1.7250 after Cantor Fitzgerald downgraded the stock from Overweight to Neutral and lowered its price target from $6 to $4.
    • Senti Biosciences, Inc. (NASDAQ:SNTI) declined 21.8% to $3.75.
    • SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) fell 20.7% to $2.26. SELLAS Life Sciences Group recently announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb’s nivolumab (Opdivo) in with malignant pleural mesothelioma (MPM).
    • Future FinTech Group Inc. (NASDAQ:FTFT) fell 20.7% to $0.3879.
    • Imperial Petroleum Inc. (NASDAQ:IMPP) dipped 20% to $0.7055. Imperial Petroleum entered into warrant exercise transaction for $21.8 million in gross proceeds.
    • Troika Media Group, Inc. (NASDAQ:TRKA) dropped 19.9% to $0.7534.
    • Ebang International Holdings Inc. (NASDAQ:EBON) declined 19.7% to $0.6017.
    • GeoVax Labs, Inc. (NASDAQ:GOVX) fell 19.7% to $1.1399.
    • SciSparc Ltd. (NASDAQ:SPRC) dropped 19.4% to $2.3214.
    • Valneva SE (NASDAQ:VALN) fell 19.2% to $16.16. Valneva said it is working on remediation plan for investigational COVID-19 vaccine.
    • Aethlon Medical, Inc. (NASDAQ:AEMD) fell 18.7% to $0.9101.
    • Marpai, Inc. (NASDAQ:MRAI) dipped 18.6% to $1.05.
    • Regis Corporation (NYSE:RGS) fell 18.4% to $0.5302. Regis shares jumped around 16% on Friday after the company announced a partnership with Zenoti.
    • Verb Technology Company, Inc. (NASDAQ:VERB) declined 18.2% to $0.36.
    • Renovacor, Inc. (NYSE:RCOR) dropped 18% to $1.4101.
    • Eros Media World Plc (NYSE:EMWP) declined 17.8% to $3.28.
    • SIGNA Sports United N.V. (NYSE:SSU) dropped 17.7% to $5.14.
    • Sphere 3D Corp. (NASDAQ:ANY) fell 17.7% to $0.7411.
    • Cumulus Media Inc. (NASDAQ:CMLS) dropped 17.7% to $9.46.
    • Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) fell 17.5% to $0.5424. Cyclerion Therapeutics shares dipped 20% on Friday after the company announced topline clinical data for CY6463 in MELAS patients at UMDF Mitochondrial Medicine 2022 Symposium.
    • Newegg Commerce, Inc. (NASDAQ:NEGG) dipped 17.3% to $4.0094.
    • Standard Lithium Ltd. (NYSE:SLI) declined 17.2% to $4.3699.
    • Renovare Environmental, Inc. (NASDAQ:RENO) dipped 17.2% to $0.2251.
    • LM Funding America, Inc. (NASDAQ:LMFA) dropped 16.8% to $0.9399.
    • Lulu's Fashion Lounge Holdings, Inc. (NASDAQ:LVLU) fell 16.8% to $11.77. B of A Securities recently downgraded Lulus Fashion Lounge from Buy to Neutral and raised the price target from $14 to $21.
    • DBV Technologies S.A. (NASDAQ:DBVT) fell 16.7% to $2.30 after declining 15% on Friday.
    • Mawson Infrastructure Group, Inc. (NASDAQ:MIGI) dropped 16.6% to $1.76.
    • Argo Blockchain plc (NASDAQ:ARBK) fell 16.3% to $4.7950 following a 5% decline on Friday.
    • Missfresh Limited (NASDAQ:MF) fell 16.1% to $0.2396.
    • CRISPR Therapeutics AG (NASDAQ:CRSP) declined 15.4% to $54.11. Stifel maintained CRISPR Therapeutics with a Hold and raised the price target from $52 to $57.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) dipped 15.3% to $3.22.
    • Coinbase Global, Inc. (NASDAQ:COIN) shares fell 14.9% to $49.96 after dropping 8% on Friday.
    • Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) dipped 14.7% to $1.28.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) fell 14.2% to $12.93.
    • Canaan Inc. (NASDAQ:CAN) fell 13.6% to $3.2224 in sympathy with the price of Bitcoin and Ethereum.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) dipped 13% to $2.01.
    • Mogo Inc. (NASDAQ:MOGO) fell 12.6% to $1.0050 after dropping 4% on Friday.
    • HIVE Blockchain Technologies Ltd. (NASDAQ:HIVE) fell 12.4% to $ 2.97 in sympathy with the price of Bitcoin and Ethereum.
    • Mainz Biomed B.V. (NASDAQ:MYNZ) fell 12.2% to $9.62.
    • Bitfarms Ltd. (NASDAQ:BITF) fell 12% to $1.40 in sympathy with the price of Bitcoin and Ethereum.
    • Hut 8 Mining Corp. (NYSE:HUT) fell 12% to $1.6550 after dropping 5% on Friday.
    • BIMI International Medical Inc. (NASDAQ:BIMI) fell 11.7% to $0.5962. BIMI International Medical shares jumped 30% on Friday after the company announced it entered a $5 million stock purchase agreement with chairman Fnu Oudom.
    • Riot Blockchain, Inc. (NASDAQ:RIOT) fell 10.3% to $ 4.6275 in sympathy with the price of Bitcoin and Ethereum.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shares fell 9.3% to $3.28 after declining around 15% on Friday.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) fell 8.9% to $0.2056.

     

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $AEMD
    $AERC
    $ANY

    CompanyDatePrice TargetRatingAnalyst
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Coinbase Global Inc.
    $COIN
    2/12/2026$120.00Buy → Neutral
    Monness Crespi & Hardt
    Hut 8 Corp.
    $HUT
    2/2/2026$80.00Buy
    H.C. Wainwright
    Coinbase Global Inc.
    $COIN
    1/28/2026$240.00Neutral
    Robert W. Baird
    Strategy Inc
    $MSTR
    1/27/2026$213.00Overweight
    Cantor Fitzgerald
    Coinbase Global Inc.
    $COIN
    1/27/2026$277.00Overweight
    Cantor Fitzgerald
    HIVE Digital Technologies Ltd.
    $HIVE
    1/27/2026$3.50Outperform → Mkt Perform
    Keefe Bruyette
    More analyst ratings

    $ABVC
    $AEMD
    $AERC
    $ANY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coinbase Global downgraded by Monness Crespi & Hardt with a new price target

    Monness Crespi & Hardt downgraded Coinbase Global from Buy to Neutral and set a new price target of $120.00

    2/12/26 7:44:13 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    $ABVC
    $AEMD
    $AERC
    $ANY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Kelly Timothy P sold $12,020 worth of shares (6,228 units at $1.93), decreasing direct ownership by 8% to 73,125 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/27/26 4:01:13 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Accounting Officer Jones Jennifer N. sold $170,122 worth of shares (1,102 units at $154.38), closing all direct ownership in the company (SEC Form 4)

    4 - Coinbase Global, Inc. (0001679788) (Issuer)

    2/26/26 4:14:47 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    Chief People Officer Brock Lawrence J sold $744,327 worth of shares (4,821 units at $154.39), decreasing direct ownership by 91% to 497 units (SEC Form 4)

    4 - Coinbase Global, Inc. (0001679788) (Issuer)

    2/26/26 4:14:21 PM ET
    $COIN
    Finance: Consumer Services
    Finance

    $ABVC
    $AEMD
    $AERC
    $ANY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AEMD
    $AERC
    $ANY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asher Daniel bought $191,162 worth of shares (15,540 units at $12.30) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/20/26 4:57:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $11,520 worth of shares (1,200 units at $9.60) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/19/26 4:03:47 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $970,069 worth of shares (102,029 units at $9.51) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/17/26 3:42:24 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $ABVC
    $AEMD
    $AERC
    $ANY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vertiv Industrializes AI Deployment with Digitally Orchestrated Infrastructure, Collaborates with Hut 8 to Scale

    Vertiv™ OneCore factory-integrated, digitally validated infrastructure reduces on-site deployment complexity and accelerates schedule certainty amid tightening construction constraints COLUMBUS, Ohio, Feb. 26, 2026 /PRNewswire/ -- Vertiv (NYSE:VRT), a global leader in critical digital infrastructure, today announced a major evolution in high-density data center deployment, shifting from traditional static modeling to a higher fidelity Digital Twin platform. This technology-first approach accelerates the deployment of its Vertiv™ OneCore integrated modular solutions, enabling operators to scale AI factories with unprecedented velocity and precision.

    2/26/26 8:00:00 AM ET
    $HUT
    $VRT
    Finance: Consumer Services
    Finance
    Industrial Machinery/Components
    Technology

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Manag

    2/26/26 7:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Strategy World 2026 Declares a New Era for Enterprise AI, Honors Customer and Partner Innovation

    Strategy Inc, a pioneer in AI-powered business intelligence, today announced key highlights from Strategy World 2026, currently taking place in Las Vegas (February 23–26). Under the theme "Freedom by Design," the event has served as a turning point for the agentic enterprise. The Death of Traditional Software In a provocative opening keynote, CEO Phong Le declared the traditional era of enterprise software, business intelligence (BI), and data warehousing effectively over. Le argued that these rigid technologies are being replaced by a new paradigm built on AI and enterprise sovereignty. "For a new era to begin, another must end. Enterprise software is broken. We are moving toward an

    2/25/26 8:38:00 PM ET
    $MSTR
    $STRC
    Computer Software: Prepackaged Software
    Technology
    Wholesale Distributors
    Industrials

    $ABVC
    $AEMD
    $AERC
    $ANY
    SEC Filings

    View All

    Sphere 3D Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Sphere 3D Corp. (0001591956) (Filer)

    2/27/26 4:05:55 PM ET
    $ANY
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SCHEDULE 13G/A filed by Marpai Inc.

    SCHEDULE 13G/A - Marpai, Inc. (0001844392) (Subject)

    2/27/26 10:13:31 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form S-3ASR filed by Rhythm Pharmaceuticals Inc.

    S-3ASR - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    2/26/26 5:37:52 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AEMD
    $AERC
    $ANY
    Leadership Updates

    Live Leadership Updates

    View All

    CISO Global Appoints Dhaval Damania as EVP of Cybersecurity & IT

    Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global's

    2/23/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    CISO Global Lands 30 Year Sales Veteran Michael Czerneda to Ignite the Next Wave of Software Growth

    New Vice President of Sales to accelerate software-driven growth across cyber services platform and insurance distribution channels  Scottsdale, Ariz., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Michael Czerneda as Vice President of Sales. In this role, Czerneda will lead enterprise-wide sales initiatives as the Company accelerates its transition toward scalable, software-driven growth built on its established cyber services platform.  Czerneda brings more than 30 years of sales leadership experience spanning UCaaS, CCaaS, da

    2/18/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    $ABVC
    $AEMD
    $AERC
    $ANY
    Financials

    Live finance-specific insights

    View All

    Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ---- Phase 2 open-label extension data showed bivamelagon achieved persistent BMI reductions at six and nine months; Completed positive end-of-Phase-2 meeting with FDA ---- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired HO in March 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in rare genetically caused melanocortin-4 receptor (MC4R) pathway diseases in March 2026 -- -- Manag

    2/26/26 7:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hut 8 Reports Fourth Quarter and Full Year 2025 Results

    Power-first model delivers first AI infrastructure transaction and advances multi-gigawatt growth strategy8,500 MW1 development pipeline as of December 31, 2025 sets foundation for scalable, repeatable execution in 2026Earnings Release HighlightsCommercialized AI infrastructure at scale, signing a 15-year, 245 MW IT lease with Fluidstack at the River Bend campus, representing $7.0 billion in base-term contract value.Refined portfolio structure and streamlined capital allocation framework through the sale of a 310 MW portfolio of four natural gas-fired power plants, which closed in February 2026, and the launch and public listing of American Bitcoin Corp., a majority-owned Bitcoin accumulatio

    2/25/26 6:30:00 AM ET
    $GS
    $HUT
    $JPM
    Investment Bankers/Brokers/Service
    Finance
    Finance: Consumer Services
    Major Banks

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AEMD
    $AERC
    $ANY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Newegg Commerce Inc.

    SC 13D/A - Newegg Commerce, Inc. (0001474627) (Subject)

    12/17/24 4:37:51 PM ET
    $NEGG
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care